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Background: Mycobacterium ulcerans (M. ulcerans) causes a devastating necrotising infection of skin tissue leading
to progressive ulceration. M. ulcerans is the only human pathogen that secretes mycolactone, a polyketide molecule
with potent cytotoxic and immunomodulatory properties. These unique features make mycolactone an attractive
biomarker for M. ulcerans disease. We sought to measure the concentration of mycolactone within lesions of
patients with Buruli ulcer before, during and after antibiotic treatment to evaluate its association with the clinical
and bacteriological response to therapy.
Methods: Biopsies of M. ulcerans infected skin lesions were obtained from patients before, during and after
antibiotic therapy. Lipids were extracted from the biopsies and concentration of mycolactone was assayed by mass
spectrometry and a cytotoxicity assay and correlated with clinical and bacteriological response to therapy.
Results: Baseline concentration of mycolactone measured by mass spectrometry predicted time to complete
healing of small nodules and ulcers. Even though intra-lesional concentrations of mycolactone declined with
antibiotic treatment, the toxin was still present after antibiotic treatment for 6 weeks and also 4 weeks after the end
of treatment for 8 weeks in a subgroup of patients with slowly healing lesions. Additionally viable bacilli were
detected in a proportion of these slowly healing lesions during and after treatment.
Conclusions: Our findings indicate that baseline intra-lesional mycolactone concentration and its kinetics with
antibiotic therapy are important prognostic determinants of clinical and bacteriological response to antibiotic
treatment for Mycobacterium ulcerans disease. Mycolactone may be a useful biomarker with potential utility in
optimising antibiotic therapy.
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Mycobacterium ulcerans infection causes Buruli ulcer, a
chronic necrotising skin infection with high prevalence
in rural West Africa. M. ulcerans infection may manifest
initially as a pre-ulcerative nodule, a plaque or as a rap-
idly progressing oedema which breaks down to form
characteristic ulcers with undermined edges. The viru-
lence of M. ulcerans is dependent on mycolactone, a lipid* Correspondence: stephensarfo78@gmail.com
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unless otherwise stated.toxin with cytotoxic or immunosuppressive properties
depending on its concentration [1-6]. Histopathology
of Buruli ulcer shows clumps of extracellular bacteria
surrounded by necrotic subcutaneous fat with little
inflammation around the organisms. Mycolactone, which
is responsible for the necrosis, is synthesised by giant poly-
ketide synthases and polyketide modifying enzymes
whose genes are carried on a 174-kb plasmid known as
pMUM001 [7]. The resulting molecule consists of a 12-
membered lactone ring with two polyketide derived side
chains. Variation in the structure of polyketide side chains
is responsible for differences in virulence/potency among
the family of mycolactones.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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broblasts [8], adipocytes [9], primary human keratino-
cytes [10] and human embryonic lung fibroblasts [11].
At lower concentrations in-vivo mycolactone suppresses
dendritic cell, macrophage and T-cell function abrogating
cytokine and chemokine secretion in response to mito-
gens [4], an effect which has been shown to be mediated
post-transcriptionally [12]. It also impairs T-cell homing
by suppressing microRNA let-7b control of L-selectin
(CD62-L) expression [13].
We have detected mycolactone associated cytotoxicity
in lipid extracts from M. ulcerans infected human sub-
cutaneous tissue and showed that mycolactone was
present by mass spectrometry [11]. M. ulcerans is the
only human pathogen known to be associated with
mycolactone secretion and therefore it may be a useful
biomarker. For instance, profound differences have been
demonstrated in time to healing of similar-sized Buruli
ulcers on standard antibiotic therapy with daily oral ri-
fampin and intramuscular streptomycin for 8 weeks [14]
and persistence of mycolactone in wounds may contribute
to this observation. In a murine model, we have recently
demonstrated that the decline in tissue mycolactone con-
centration during antibiotic therapy tracked closely with
reduction in colony forming units of M. ulcerans and with
resolution of footpad swelling, highlighting the close
association between mycolactone and pathogenesis of
M. ulcerans disease [15]. In the present studies we have
investigated the dynamics of clearance of mycolactone
from skin tissues during curative antibiotic treatment in
order to provide proof-of-principle data on the prognostic
potential of mycolactone as a biomarker.
Methods
Ethical statement
The study protocol was approved by the ethics review
committee at the School of Medical Sciences, Kwame
Nkrumah University of Science and Technology, Kumasi,
Ghana. All patients provided written informed consent
before inclusion into the study. For minors informed
consent was obtained from parents or guardians on
their behalf.
Subjects and samples
Eighty (80) patients with PCR confirmed diagnosis of
M. ulcerans disease recruited from villages around the
Ahafo Ano North, Ashanti Akim North and Nkawie
districts at the Tepa Government Hospital, the Agogo
Presbyterian Hospital and the Nkawie Government
Hospital of the Ministry of Health, Ghana were selected
for this study. After the patients had given informed con-
sent, a fine needle aspiration and two 4 mm punch biopsies
were obtained from the centre of non-ulcerated lesions
or from the edge of the viable skin around ulcers afterapplication of a topical anaesthetic for 15 minutes. The
fine needle aspirate was used to confirm the diagnosis by
PCR. One punch biopsy was used to perform microscopy
and quantitative culture and the other biopsy was placed
in amber-coloured tubes, snap frozen in liquid nitrogen
and stored at -70°C for lipid extraction to detect and
quantify mycolactone. Patients were treated with antibi-
otics for 8 weeks, either using the combination of rifampin
and streptomycin throughout (RS8) or substituting ri-
fampin plus clarithromycin after 2 weeks (RS2RC6). In
consenting adults two further biopsies were obtained,
one for quantitative culture and one for lipid extrac-
tion and mycolactone quantification at 6 weeks during
antibiotic therapy and, from lesions which had not healed,
at 12 weeks.
Diagnostic confirmation of M. ulcerans disease in study
subjects
PCR was performed on fine needle aspirates from in-
fected tissue targeting the IS2404 insertion sequence of
M. ulcerans as described elsewhere [16]. The PCR was
based on the IS2404 insertion element; PU4F (5′-GCGCA
GATCAACTTCGCGGT-3′) and PU7Rbio (5′-GCCCGA
TTGGTGCTCGGTCA-3′) were used as primers. Micro-
scopic examination to detect M. ulcerans was performed
by homogenising skin biopsy tissue obtained by punch
biopsy and staining by the Ziehl-Neelsen technique. For
quantitative culture, 1 ml of homogenized tissue was
decontaminated by the modified Petroff method for
10 minutes after which four 10-fold serial dilutions were
prepared and 100 μl of homogenate at each concen-
tration was inoculated in triplicate onto Löwenstein-
Jensen slopes. The remaining tissue homogenate at each
dilution was also inoculated and cultures were incubated
at 31°C and examined weekly for 6 months before they
were discarded. Positive cultures were tested for IS2404 to
confirm the identity and presence of M. ulcerans.
Monitoring the clinical response to antibiotic treatment
The maximum diameter of the lesion and the diameter
at right angles were measured and the average diameter
was used. Lesions were categorised as category I when
the average diameter was less than 5 cm, category II be-
tween 5 to 15 cm and category III more than 15 cm in
diameter or multiple lesions. The clinical response to
antibiotic treatment was monitored every two weeks to
establish the time to complete healing and monthly
thereafter for one year from completion of antibiotic
treatment to check for recurrences. For ulcerative le-
sions, time to healing was defined as time to complete
re-epithelialization or stable scab formation whereas for
nodular lesions, time to healing was defined as time to
complete resolution such that no visible or palpable le-
sion remained.
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detection and quantification
Lipids were extracted from skin biopsies from Buruli
lesions using chloroform: methanol 2:1 (vol/vol) followed
by a Folch extraction with 0.2 volumes water as previously
described [11]. Briefly, the punch biopsy was weighed
and placed in a 1.5 ml green top matrix tube contain-
ing 500 μl of diatoms (Q-bio) and homogenised in
extraction solution for 45 seconds at a power of 6.5
in a Fast Prep Ribolyser. The homogenate was transferred
into a microfuge tube and allowed to stand for 30 minutes.
After centrifugation at 10,000 g for 15 minutes the organic
phase was harvested. The organic phase was dried in a
roto-evaporator and re-suspended in ice-cold acetone for
1 hour to precipitate phospholipids. Acetone soluble lipids
(ASL) suspended in 100 μl ethanol for mycolactone detec-
tion by mass spectrometry and cytotoxicity assays were
kept in amber-coloured Eppendorf tubes at -80°C until
analyses were performed. To determine the efficiency of
the extraction technique, 4 mm punch biopsies from an
excised human breast tissue (obtained with permission
from Department of Surgery) were spiked with 1ug of syn-
thetic mycolactone A/B and subjected to extraction as de-
scribed above.
Quantitative cytotoxicity assay
Mycolactone present in ASL from tissues were quantified
using the MTT assay, a colorimetric test that measures
cellular metabolic activity of human embryonic lung
fibroblasts (HELF) [11,15,17] as previously described.
Briefly HELF cells (kindly donated by Dr. Kay Capaldi)
were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% foetal calf serum and 2 mM L-
glutamine in the presence of penicillin and streptomycin
100 mU/ml and 100 mg/ml respectively and incubated in
5% carbon dioxide at 37°C. For cytotoxicity assays prolifer-
ating HELF cells were seeded at a density of 105/well in
microtitration plates overnight.
ASL from lesions, positive controls (purified mycolac-
tone, synthetic mycolactone and mycolactone spiked hu-
man skin tissue) and negative controls (lipids from an
excised breast tissue obtained at mastectomy) were dis-
solved in 100 μl of absolute ethanol and 2-fold dilutions
performed up to the 5th dilution. 5 μl of each dilution
was used to treat HELF cells in triplicate. After incuba-
tion, 20 μl of 5 mg/ml MTT (Sigma) was added to each
well and incubated for a further 4 h for purple coloured
formazan crystals to develop following which 100 μl iso-
propanol: HCl (2 N) was used in a ratio of 49:1 to dissolve
formazan crystals for spectrophotometric quantification in
a multiplate well reader at 570-690 nm. Time course and
dose-response calibration curves of mycolactone mediated
cytotoxicity on HELF cells were performed by treating
HELF cells over 24, 48 and 72 hours with serial dilutionsof purified or synthetic mycolactone A/B (kind gifts of
Dr. Caroline Demangel, Pasteur Institute, Paris, France
and Professor Y Kishi, Harvard University, USA respect-
ively) up to concentration of 250 ng/ml following which
curve-fitting plots were constructed. In order to evaluate
non-specific cytotoxicity caused by other skin lipids, lipid
extracts from non-infected human skin were tested for
cytotoxicity and this was set as the lower limit of detection
for the cytotoxicity assay. All calibration and quantifica-
tion experiments were performed three times.
Characterization and quantification of mycolactone A/B
by UPLC tandem mass spectrometry
Liquid chromatographic separation and tandem mass
spectrometric detection were performed using an ABI
Sciex 3200 Q Trap mass spectrometer (ABI Sciex, UK)
interfaced with a Shimadzu UFLC system (UFLC XR sys-
tem with CBM-20A controller, SIL-20 AC XR Prominence
autosampler, CTO-20 AC Prominence column oven and
LC-20 AD XR pumps (Shimadzu, UK). For the analysis of
lipid extracts from clinical specimens, positive and nega-
tive controls, UPLC was combined with enhanced product
ion identification (LC-EPI) or multiple reaction monitor-
ing (LC-MRM) as previously described (15).Statistical analysis
Medians were compared using the Mann-Whitney’s
U-test for two independent continuous variables. Corre-
lations between two independent variables were analyzed
using Pearson’s correlation test. GraphPad Prism version 4
software was used for all analysis with p < 0.05 considered
statistically significant.Results
Demographics, diagnostic and clinical data of study
participants
Eighty patients with clinically confirmed M. ulcerans
disease were included with median age of 14 years
(range 5 – 70 years) and male to female ratio 1:1. There
were 18 (22.5%) nodules, 14 (17.5%) plaques, 44 (55.0%)
ulcers and 4 (5.0%) oedematous lesions (Table 1). There
were 50 (62.5%) category I lesions, 23 (28.8%) category II
lesions and 7 (8.7%) category III lesions. The median re-
ported duration of lesions before presentation was 3 weeks
(range 1–32 weeks) with no significant differences be-
tween the clinical forms of M. ulcerans disease. PCR for
IS2404 was positive in all patients; 40 out of 60 cultures
for M. ulcerans (66%) were positive and acid-fast bacilli
were positive in 25 out of 60 (42%) samples tested before
antibiotic therapy. The median time to healing of lesions
in patients treated with RS2RC6 was 16 weeks (interquar-
tile range (IQR) 4–36) [18]. Among patients who received
rifampin and streptomycin for 8 weeks, the median time
Table 1 Demographic, diagnostic and clinical data of study participants











Male: Female 12:6 5:9 2:2 22:22 41:39
Median (range) age 13.5 (5-48) 12 (5-70) 16 (7-55) 16 (5-59) 14 (5-70)
Lesion category
Category 1(< 5 cm) 18 10 0 22 50
Category 2 (5-15 cm) 0 4 2 17 23
Category 3 (> 15 cm) 0 0 2 5 7
Median (range) duration of lesion (weeks) 4 (1 – 12) 3 (1-12) 3.5 (3-4) 3 (1 – 32) 3 (1 – 32)
PCR result: no. of positive tests 18 14 4 44 80
Culture result (+: - : nd) 8:6:4 8:5:1 1:1:2 23:8:13 40:20:20
Microscopy result (+: - : nd) 7:7:4 6:7:1 0:2:2 12:19:13 25:35:20
Median (range) time to healing (weeks) 8 (4–32)1 31 (2–48)2 8 (6-12)3 13 (5-44)4 12 (2-48)
Recurrence 1 year after treatment 0 0 0 0 0
nd = not done.
1Excluding one patient lost to follow up.
2Excluding one patient whose lesion had not healed after 52 weeks and required surgery.
3Excluding two patients with extensive oedematous disease who required skin grafting.
4Excluding four patients lost to follow up and 2 ulcers that required skin grafting.
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cantly different.
Experimental data on assays for detection and
quantification of mycolactone
Cytotoxicity assay
Mycolactone mediated cytotoxicity on human embry-
onic lung fibroblasts followed a sigmoidal dose response
at 24, 48 and 72 h (see Additional file 1: Figure S1A)
and incubation for 48 hours resulted in optimal best-fit
plots (r2 = 0.98) even though inter-assay variations were
observed in the quantities of mycolactone measured by
the cytotoxicity assay (see Additional file 1: Figure S1B).
Synthetic mycolactone induced 50% cytotoxicity at a
concentration of 4.7 ng/ml. The lower limit of detection
was set at 20% cytotoxicity to exclude non-specific cyto-
toxicity. This lower limit was set by measuring the cyto-
toxicity induced by lipid extracts from uninfected skin
tissue used as negative control.
Mass spectrometry
Mycolactone detected in skin extracts showed the same
mass spectra as those of synthetic mycolactone A/B and
also contained a number of other mycolactone associated
ions (e.g. m/z 659.6 and 747.7) (see Additional file 1:
Figure S2). Figure 1 in Additional file 1 also shows ex-
tracted ion chromatograms (XIC) of the m/z 429.6 ion se-
lected for quantification of mycolactone by LC-MRM
analysis. EPI mass spectra indicated a propensity of
authentic mycolactone A/B to form a sodium adduct
(m/z 765.7, (M +Na+), (see Additional file 1: Figure S2).Fragment ions at m/z 429.6 and 359.5 correspond to
the core lactone and polyketide side chains respect-
ively. Mycolactone A/B detected in skin extracts displayed
similar mass spectra and also contained a number of other
ions (e.g. m/z 659.6 and 747.7) that were present in au-
thentic reference material. m/z 747.7 is derived from m/z
765.7 with loss of water and generates m/z 659.6 with loss
of C4H9O2. The lower limit of detection of mycolactone
A/B by mass spectrometry was 10 pg.
Recovery of mycolactone from spiked skin tissue
The recovery of synthetic mycolactone A/B from spiked
skin tissue was 11-18% for a 1 μg spiked skin sample (n = 3
independent experiments) using mass spectroscopy
compared with a recovery of 64-100% (n = 3 independent
experiments) using the cytotoxicity based method of
quantification. Mycolactone concentration from lipid
extracts from each 4 mm skin biopsy was expressed
as ng/ml.
Mycolactone detection and concentration in M. ulcerans
infected human skin lesions
In untreated nodules, plaques, ulcers and oedematous
lesions
Compared with the conventional PCR for IS2404, the
sensitivity of mycolactone detection was 92% by cytotox-
icity and 77% by mass spectrometry. The median (range)
concentration of mycolactone in 80 untreated lesions
measured by mass spectrometry was 26 ng/ml (0-1970),
significantly lower than that measured by cytotoxicity at
439 ng/ml (136–3020) (p < 0.0001). Figure 1 shows the
Figure 1 Mycolactone concentration in punch biopsies of untreated M. ulcerans disease lesions before antibiotic treatment.
(A) Mycolactone concentration in ASL measured by cytotoxicity assay using synthetic mycolactone A/B generated calibration curves.
Horizontal lines represent medians and each dot represents one lesion. (B) Mycolactone concentration in punch biopsies of untreated
M. ulcerans disease lesions before antibiotic treatment. Mycolactone A/B concentration in ASL measured by multiple reaction monitoring
(MRM) methodology with liquid chromatographic separation coupled to a tandem mass spectrometer. Horizontal lines represent medians
and each dot represents one lesion.
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lesions before antibiotic treatment. There was a wide
variation of concentration in all types of lesion withmedian (range) of 437 ng/ml (136–2589; n = 18) in
nodules, 311 ng/ml (148-834; n = 14) in plaques, 443 ng/
ml (114–3020; n = 44) in ulcers and 895 ng/ml (457-
Sarfo et al. BMC Infectious Diseases 2014, 14:202 Page 6 of 10
http://www.biomedcentral.com/1471-2334/14/2022689; n = 4) in oedematous lesions using the cytotoxicity
assay (Figure 1A). Using mass spectrometry, the median
concentration in nodules and plaques was significantly
higher than that in ulcers (Figure 1B) whereas there was
no significant difference by cytotoxicity (Figure 1A). Cyto-
toxicity was high among the four oedematous lesions but
the amounts of intact mycolactone detected by mass spec-
trometry were low.
Distribution of mycolactone within infected tissues
Mycolactone concentration was measured by cytotox-
icity in paired biopsies taken from the centre and the
periphery of six pre-ulcerative lesions (3 nodules and 3
plaques). There was a trend towards a centripetal gradient
in 5 out of 6 lesions. The median (range) concentration of
mycolactone by mass spectrometry at the centre was
110 ng/ml (18-285), significantly higher than 26 ng/ml
(0-75) at the periphery (p < 0.05).
Mycolactone concentration during and after antibiotic
therapy
Further biopsies were taken at 6 and/or 12 weeks from
patients whose lesions were healing slowly. Median con-
centration of mycolactone by cytotoxicity decreased
from 479 ng/ml (range 159-3020; n = 26) at week 0 to
385 ng/ml (153-1160, n = 23) (p < 0.05) at 6 weeks and to
320 ng/ml (169-604; n = 7) (NS) at 12 weeks (Figure 2A).
By mass spectrometry, the median concentration de-
creased from 34 ng/ml (range 0–296) at week 0 to 16 ng/ml
(0-226) (p < 0.05) at week 6 and to 3 ng/ml (0-27) (NS) at
week 12 (Figure 2B).
Correlation between healing time and mycolactone
concentration at baseline
There was a weak but significant correlation between
mycolactone measured by mass spectrometry at baseline
with time to complete healing (Pearson’s correlation co-
efficient 0.24; p = 0.05). A stronger correlation between
time to healing and category I lesions (r = 0.34, p = 0.02),
among nodular lesions (r = 0.57, p = 0.02) and category
I ulcerative lesions (r = 0.68, p = 0.001) in particular
(Figure 3A-D) were noted. Nodules with mycolactone
concentration below 64.9 ng/ml (the median value)
healed in 8 weeks (range 4-32) compared with 12 weeks
(6-52) for those with mycolactone concentration above
the median (p < 0.05).
Mycolactone detection in lesions sampled for M. ulcerans
culture
Samples were taken for culture of M. ulcerans from 60
patients before antibiotic treatment, 15 patients at week
6 during antibiotic therapy and 3 patients at week 12
(i.e. 4 weeks after completing antibiotic treatment).
The results of culture and mycolactone detection atweeks 0, 6 and 12 are shown in Table 2. Before anti-
biotic therapy, 66% of PCR positive lesions were also
culture positive whilst cytotoxicity was detected in
87% of lesions and mycolactone was detected by mass
spectrometry in 70% of lesions in this subset of 60
patients. Despite higher overall sensitivity, mycolac-
tone was not detected in some samples that were cul-
ture positive at week 0; 5 by cytotoxicity and 14 by mass
spectrometry. At week 6, mycolactone was present in 7
culture negative samples using both the cytotoxicity assay
and mass spectrometry. At week 12, mycolactone was de-
tected by cytotoxicity in 2 culture positive lesions but
mass spectrometry was negative.Discussion
Our study has highlighted the potential importance of
mycolactone detection and quantification in infected hu-
man subcutaneous tissue as a tool in understanding the
pathogenesis of Buruli ulcer disease and in refining anti-
biotic treatment. Using mass spectrometry, significantly
higher concentrations of mycolactone were detected in
nodules and plaques, the early forms of M. ulcerans dis-
ease, than in ulcers. There was considerable variation in
mycolactone concentration in these lesions (Figure 1A
and 1B) which may reflect differences in the duration of
infection and bacterial burden at presentation; if the pa-
tient had been infected recently, the lesions would be ex-
pected to contain a lower load of bacilli secreting
mycolactone. There was some correlation between con-
centration of mycolactone A/B and healing time in this
sub-group and this could be an important observation
for planning treatment.
In the small number of oedematous lesions studied,
there was a low concentration of mycolactone A/B by
mass spectrometry but high cytotoxicity. This is the least
common but most aggressive form of early M. ulcerans
disease in which oedema spreads rapidly to adjacent
areas leading to formation of large ulcers. The pathogen-
esis of the oedema is unknown but the discrepancy be-
tween mycolactone concentration by mass spectrometry
and the cytotoxicity assay suggests that either there was
a high turnover of mycolactone or that an anomalous
host response to M. ulcerans infection generated cyto-
toxic lipid molecules of a different sort. This needs fur-
ther investigation.
The centripetal gradient of mycolactone concentration
from high in the centre to low in the periphery of pre-
ulcerative lesions is compatible with the clinical observa-
tion that lesions tend to break down in the centre to
form ulcers but variations in mycolactone concentration
have to be interpreted with caution since only a small
number of samples could be taken for ethical reasons.
Sampling error is an unavoidable problem in studies of
Figure 2 Tissue mycolactone concentration in serial biopsies during and after antibiotic treatment. Antibiotic treatment was
started at week 0 and completed at week 8. Biopsies were taken at weeks 0 in all patients and at week 6 and/or 12 when it was
clinically indicated. (A) Mycolactone concentration in ASL measured by cytotoxicity assay using synthetic mycolactone A/B generated
calibration curves. (B) Tissue mycolactone concentration in serial biopsies during and after antibiotic treatment. Mycolactone A/B
concentration in ASL measured by multiple reaction monitoring (MRM) methodology with liquid chromatographic separation coupled to
a tandem mass spectrometer.
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tried to limit it by studying a large number of patients.
Mycolactone associated cytotoxicity was still positive
in some biopsies obtained 6 weeks into antibiotic ther-
apy and 4 weeks after its completion from a subset of
slowly healing lesions and in some cases M. ulceranscultures were also positive (Table 2). Mycolactone A/B
was detectable in most of the 6 week samples but not at
12 weeks. This may indicate that a proportion of pa-
tients with slowly healing lesions still had viable bacteria
in the skin late in the course of treatment and some of
these lesions also had positive cultures for M. ulcerans.
Table 2 Mycolactone detection by mass spectrometry and cytotoxicity assay in patients with M. ulcerans disease
sampled for M. ulcerans culture
Time Week 0 Week 6 Week 12
Mycolactone
detection
Culture result Culture result Culture result
Positive Negative Positive Negative Positive Negative
Cytotoxicity positive 35 17 7 7 2 0
Cytotoxicity negative 5 3 0 1 0 1
Total (1) 40 20 7 8 2 1
MS positive 26 16 6 7 0 0
MS negative 14 4 0 1 2 1
Total (2) 40 20 6 8 2 1
MS - Mass spectrometry. Total (1) represents sub-total of comparison of mycolactone detection by cytotoxicity and culture results. Total (2) represents sub-total of
comparison of mycolactone detection by mass spectrometry and culture results.
Figure 3 Correlation between baseline mycolactone A/B concentration measured using mass spectrometry and time to complete
healing. (A) All categories and forms of buruli lesion. (B) All category I lesions. (C) Nodular lesions. (D) Category I ulcers (less than 5 cm
in widest diameter).
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after the bacteria were killed but the fact that we also
found some positive cultures after antibiotic treatment
argues against this. To resolve this question further work
will be needed using new techniques for detecting viable
M. ulcerans such as the combined 16S rRNA and IS2404
assay [19].
In an earlier study, cultures of excised nodules and
plaques from patients with early Buruli ulcer disease
treated with streptomycin and rifampicin for periods
varying from 2 to 8 weeks were culture negative from
4 weeks onwards [20]. This difference may be explained
by the fact that patients with all forms of the disease
were included in the present study. There was no differ-
ence between the RS8 and RS2RC6 groups with regard
to the number of samples positive for mycolactone or
bacterial culture at 6 or 12 weeks and the median time
to healing was similar so it is unlikely that slow healing
was due to reduced exposure to streptomycin [21].
Clinical observations have shown that some small Bur-
uli lesions take a considerable time to heal with anti-
biotic therapy [14,22] and our study has provided some
evidence to explain these observations. The persistence
of mycolactone within Buruli lesions during and after
antibiotic therapy could retard healing by killing kerati-
nocytes [23] and by inhibiting the secretion of growth
factors required for wound healing [24]. At the molecu-
lar level, mycolactone has recently been shown to bind
to the Wiskott-Aldrich syndrome protein (WASp) in
epithelial cells, provoking uncontrolled activation of
Arp2/3. This disrupts assembly of actin in the cytoplasm
resulting in defective cell adhesion which could lead to
defective wound closure [25]. Compounds that inactivate
mycolactone might therefore play an adjunctive role in
promoting healing of Buruli ulcers.
Detection of viable organisms may be an important
tool for determining the optimal duration of antibiotic
treatment and the present study suggests that mycolac-
tone measurement may have a role in this. Early lesions
containing low numbers of viable organisms may be
cured by antibiotic treatment for less than the standard
8 weeks and, on the other hand, ulcers still containing
mycolactone at 6 weeks may require more prolonged
treatment.
Conclusions
We have shown that the baseline concentrations of tis-
sue mycolactone as well as its kinetics during and after
antibiotic therapy are important determinants of clinical
response to treatment. Significantly, slowly healing le-
sions which were found to contain mycolactone also fre-
quently had viable bacilli late into the recommended
8-week course of antibiotic therapy. In conclusion the
measurement of tissue mycolactone is a promising newmethod of monitoring the clinical response to antibiotic
therapy which may lead to new insights into the patho-
genesis of M. ulcerans disease as well as guiding future
treatment developments.
Additional file
Additional file 1: Experimental data on mycolactone quantification
assays. Figure S1A and 1B shows dose- and time-course experiments
of mycolactone mediated cytotoxicity on human embryonic lung
fibroblasts (HELF). 1A shows best-fit plots and 1B shows raw data plots.
Figure S2 shows mass spectrometry data on mycolactone quantification.
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